Sio Capital Management LLC Buys New Shares in NeuroOne Medical Technologies Corporation $NMTC

Sio Capital Management LLC bought a new position in shares of NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 3,523,663 shares of the company’s stock, valued at approximately $2,390,000. NeuroOne Medical Technologies makes up about 0.9% of Sio Capital Management LLC’s portfolio, making the stock its 28th biggest position. Sio Capital Management LLC owned approximately 7.07% of NeuroOne Medical Technologies at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. XTX Topco Ltd acquired a new position in shares of NeuroOne Medical Technologies during the second quarter valued at about $51,000. Warberg Asset Management LLC bought a new stake in NeuroOne Medical Technologies in the 2nd quarter valued at about $27,000. Finally, Goldman Sachs Group Inc. acquired a new position in NeuroOne Medical Technologies during the 1st quarter worth approximately $84,000. 16.07% of the stock is owned by institutional investors.

NeuroOne Medical Technologies Stock Down 2.0%

Shares of NASDAQ:NMTC opened at $0.68 on Tuesday. The business’s 50 day moving average is $0.80 and its 200 day moving average is $0.76. NeuroOne Medical Technologies Corporation has a 12-month low of $0.40 and a 12-month high of $1.39. The stock has a market cap of $34.06 million, a price-to-earnings ratio of -4.54 and a beta of 0.71.

Analyst Upgrades and Downgrades

NMTC has been the subject of a number of research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of NeuroOne Medical Technologies in a research note on Wednesday, October 8th. Maxim Group started coverage on NeuroOne Medical Technologies in a report on Tuesday, September 9th. They issued a “buy” rating and a $3.00 target price on the stock. Finally, Wall Street Zen upgraded shares of NeuroOne Medical Technologies to a “hold” rating in a research note on Friday, October 3rd. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $2.23.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders.